Three Phase 3 trials hit their primary endpoints in the span of two weeks. The stock is sitting roughly a third below its 52-week high. Those two facts sit in tension, and examining what the filed evidence says about each is the purpose of this analysis.
Mirum Pharmaceuticals began life as a single-drug bet on a rare liver disease that most gastroenterologists had never treated. LIVMARLI, its flagship medicine for a condition called Alagille syndrome that traps bile in children’s livers and causes relentless itching, generated $19 million in its first full year of sales. Five years later, the company is guiding for nearly $700 million in 2026 revenue, has four FDA-approved products, and just reported three consecutive Phase 3 wins in a fortnight. That is a genuinely unusual run. The question the filed numbers raise is whether the market has already decided the run is over.
What matters here
The math shows a company that has grown revenue roughly 27-fold in four years and is closing fast on its first profitable year. The mood, meaning what today’s price implies about the future, values the business well below its own historical median, according to our data. Three late-stage trials just succeeded on the same day the stock trades at a multi-year discount to its own norms. One open question the filed evidence raises is whether the assumptions embedded in today’s price are consistent with the trajectory the filings describe, a question this analysis lays out but does not resolve.
From one drug to four, in five years
The turning point that built today’s Mirum came in September 2021, when the FDA cleared LIVMARLI for the itch that Alagille syndrome causes in children. That approval gave the company its first commercial product and its first real revenue line. What followed was not a slow build. Full-year 2025 revenue reached $521 million, with LIVMARLI alone contributing the majority and a portfolio of bile acid medicines adding the rest. Revenue has roughly tripled since 2023, and each doubling has come faster than the one before it.
Then September and October 2026 arrived in a rush. On September 25, the FDA approved Atebrioz, Mirum’s treatment for fibrodysplasia ossificans progressiva, a condition where the body slowly replaces muscle and connective tissue with bone. Three days later, the AZURE-1 Phase 3 trial of brelovitug in chronic hepatitis delta, a severe liver infection, met its primary endpoint. And today, October 12, the EXPAND Phase 3 study of LIVMARLI in additional ultra-rare cholestatic liver diseases met its primary endpoint, with treated patients showing more than twice the itch reduction of those on placebo and a bile acid reduction dramatically larger than the essentially flat result in the control group. A supplemental drug application for that label expansion is planned for the first half of 2027.
For a company built around rare liver diseases, three Phase 3 wins in two weeks is the equivalent of a small construction firm finishing three skyscrapers simultaneously. Each success opens a new patient population, and rare-disease drugs typically face thin competition and carry premium prices. That commercial logic is why the pipeline matters so directly to anyone weighing this business.
What the filings show about the money
The Q2 2026 filing shows the first half of 2026 tracking well ahead of the prior year, and the company has twice raised its full-year guidance, now targeting $680 million to $700 million, another year of strong double-digit growth on top of an already large step up in 2025. Cash on hand at June 30 was $561 million, enough, management stated in the filing, to fund operations for at least twelve months without raising new money.
The net margin tells the more interesting story. In 2023, Mirum lost nearly 88 cents on every dollar it brought in. By 2025, that loss had narrowed to less than five cents per dollar. The company is not yet profitable, but the trajectory is steep and consistent. Think of it like a restaurant that spent years building its kitchen: the fixed costs are largely sunk, and each new dollar of revenue now flows through at a far better rate than the early years suggested was possible.
R&D spending remains heavy relative to revenue, which is the price of running multiple Phase 3 programs simultaneously. That spending also explains why the company issued a large slug of convertible notes earlier this year, a form of debt that converts to equity under certain conditions, to keep the pipeline funded without immediately diluting shareholders.
Where the mood and the math diverge
The mood, meaning what investors are currently willing to pay per dollar of sales, sits at ten times annual revenue according to our data. That sounds like a large number in isolation. But Mirum’s own historical median, across the years our data covers, is closer to seventeen times. The combination of a below-historical-median multiple and a period of strong pipeline results is a data point the framework surfaces for readers to weigh against their own analysis.
The analyst community has noticed. RBC Capital and H.C. Wainwright both revised their valuation estimates upward on October 8, and Raymond James reiterated a positive view on the stock as of today, according to Investing.com Canada. S&P Global’s poll of more than a dozen analysts showed a wide dispersion of estimates; the range of those estimates and the assumptions underlying them are noted here as one input into the broader valuation picture, not as a directional signal. Sam Mancini of Seeking Alpha, writing in mid-September, took the contrarian view, arguing that the stock’s price already embedded expectations of additional approvals beyond routine label maintenance. The EXPAND data announced today is one piece of evidence relevant to evaluating that thesis; whether it is sufficient to alter the underlying valuation math depends on assumptions about pricing, market size, and competitive dynamics that the filing does not resolve.
We note one genuine competitive complication: GSK’s Lynavoy entered the cholestatic pruritus market for primary biliary cholangitis in early 2026, and Gilead’s Hepcludex received FDA clearance for chronic HDV around the same time, the same indication Mirum’s brelovitug is now targeting. Competition in rare disease is rarely winner-take-all, but it does constrain pricing power and market share assumptions. The data cannot yet tell us how these rivalries resolve.
Reading the numbers
- $521 million, full-year 2025 revenue (filed in the 10-K for fiscal year ended December 31, 2025). What it is: total product sales across all approved medicines. What it means here: the company grew from $19 million to $521 million in four years, a pace that almost no commercial-stage drug company sustains. In everyday terms: if a local bakery went from selling 19 loaves a day to 521 loaves a day in four years, the question stops being “can they bake?” and starts being “how big is the town?”
- Net margin of -4.5% in 2025, versus -88% in 2023 (our data, computed from filed figures). What it is: the share of each revenue dollar left after all costs. What it means here: the losses are nearly gone. A margin moving from -88% to -4.5% in two years means the business model is working; the fixed costs are being absorbed. In everyday terms: a household that was spending $1.88 for every dollar it earned is now spending $1.04, still in the red, but the direction is unmistakable.
- Price-to-sales of 10.0 versus historical median of 16.7 (our data). What it is: the price-to-sales ratio is the market’s price tag per dollar of annual revenue, a multiple used when a company has no profits yet. What it means here: the market is paying less per dollar of Mirum’s sales today than it has on average across its own history, even as the pipeline is delivering its strongest results. In everyday terms: a collector paying less for a painting today than they paid five years ago, while the painter has just won three major prizes.
- $561 million cash at June 30, 2026 (filed in the 10-Q for the quarter ended June 30, 2026). What it is: unrestricted cash, equivalents, and investments. What it means here: more than a full year of R&D spending sits on the balance sheet, which means the pipeline programs do not require immediate new financing. In everyday terms: a family with a year’s worth of expenses already saved can keep the lights on while they wait for a raise.
Sources
- 10-Q for quarter ended June 30, 2026 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2025 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2023 (SEC EDGAR)
- Atebrioz FDA approval announcement, Mirum IR
- EXPAND Phase 3 results, National Law Review
- AZURE-1 results investor call, BioSpace
- RBC Capital analyst rating update, Investing.com Canada
- Competitive landscape, FiercePharma
